Pfizer’s $23 Billion Bet on Cancer: 'We’ll Save the World from Cancer'

Pfizer CEO Albert Bourla announced the company’s $23 billion pivot to cancer research, declaring, 'We saved the world from COVID, now we’ll save the world from cancer.' This strategic shift was triggered by COVID-related revenues reaching $56 billion in 2022, only to plummet to $12 billion by 2023. Bourla called 2023 'a very difficult period for me' but emphasized, 'Winners never fall; winners always stand up again.' Pfizer is redirecting 40% of its R&D budget to oncology, with Bourla highlighting breakthroughs in doubling survival rates for bladder, prostate, and colorectal cancers. He credited AI and machine learning for cutting Paxlovid’s development time from four years to four months. 'Stop arguing why something’s impossible and start finding solutions,' he told his team. Beyond cancer, Pfizer is aggressively expanding into the obesity market, acquiring Metsera to boost GLP-1 treatments. Bourla described the Metsera acquisition as a 'Game of Thrones-style bidding war' and emphasized Pfizer’s commitment to innovation.

Pfizer’s cancer-focused strategy reflects a survival play amid patent cliffs and declining COVID revenues, positioning the company for long-term growth while intensifying competition in the sector.